Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BLZ945 |
Synonyms | |
Therapy Description |
BLZ945 is a selective inhibitor of CSF1R, which potentially leads to a decrease in tumor associated macrophages (PMID: 24498562, PMID: 29930294). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BLZ945 | BLZ-945|BLZ 945 | CSF1R Inhibitor 28 | BLZ945 is a selective inhibitor of CSF1R, which potentially leads to a decrease in tumor associated macrophages (PMID: 24498562, PMID: 29930294). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 loss | glioblastoma | sensitive | BLZ945 | Preclinical | Actionable | In a preclinical study, treatment with BLZ945 demonstrated some efficacy, specifically a 56% tumor reduction, in transgenic mouse models of glioblastoma with a loss of TP53 (PMID: 27199435). | 27199435 |
PTEN loss | glioblastoma | no benefit | BLZ945 | Preclinical | Actionable | In a preclinical study, BLZ945 resulted in limited benefit in transgenic mouse models of glioblastoma harboring a loss of PTEN (PMID: 27199435). | 27199435 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02829723 | Phase Ib/II | BLZ945 BLZ945 + Spartalizumab | Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | Terminated | USA | ITA | ISR | ESP | CHE | 3 |